Treatment in concordance with National Comprehensive Cancer Center (NCCN) guidelines for anal squamous cell carcinoma was associated with improved disease-specific and overall survival, according to a study presented at the virtual 2021 ASCO Gastrointestinal Cancers Symposium.
Priyanka Kumar, MD, University of California, Irvine, and colleagues aimed to analyze NCCN guideline adherence for anal squamous cell carcinoma in California and the subsequent impact on patient survival in this study.
The California Cancer Registry was used to identify patients diagnosed with anal squamous cell carcinoma between January 1, 2004 and December 31, 2017. Researchers determined whether patients received NCCN guideline-adherent care.
A total of 4740 patients with anal squamous cell carcinoma were identified. Of whom, 926 (19.5%) did not receive NCCN guideline-adherent care.
Patients who did not receive guideline-adherent care had worse disease-specific (HR 1.96, 95% CI = 1.56, 2.46, P <.0001) and overall survival (HR 1.87, 95% CI = 1.66, 2.12, P <.0001).
Patient factors associated with disease-specific and overall survival included female gender, black race, Medicare/Medicaid, and socioeconomic status.
“NCCN guideline-adherent care was associated with improved disease-specific and overall survival in anal SCC patients in California,” Dr Kumar and colleagues concluded.
Kumar P, Del Rosario M, Chang J, et al. Population-based analysis of National Comprehensive Cancer Network (NCCN) guideline adherence for patients with anal squamous cell carcinoma in California. Presented at: the virtual 2021 ASCO Gastrointestinal Cancers Symposium; January 15-17, 2021. Abstract 1.
